Clinical trial · Interventional
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol
NCT01609179CI-TRIAL-00008496completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A treatment protocol that enables patients to have continued access to IPI-926.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
| Chondrosarcoma | Chondrosarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IPI-926 | Drug | Patidegib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IPI-926
- interventionNames
- Drug: IPI-926
Primary outcomes (1)
- measure
- Incidence of adverse events (AEs) and serious adverse events (SAEs), and laboratory test results
- timeFrame
- Up to 30 days after the last patient study visit
- description
- Monitoring of AEs, including SAEs as well as review of laboratory sample test data to assess safety and tolerability of IPI-926
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Voluntarily sign the informed consent form 2. Currently receiving IPI-926 while participating in an Infinity-sponsored IPI-926 study. Note: For blinded studies, patient's treatment assignment must be unblinded according to the instructions in the original protocol to confirm they are receiving IPI-926. 3. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. 4. Documented response or stable disease, as defined in the original protocol, at the time of entry to the extension study. 5. Willingness and ability to continue IPI-926 dispensation and follow-up procedures at the current investigational site. 6. Willingness and ability to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures. 7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum or urine pregnancy test prior to treatment. All WCBP, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study. Exclusion Criteria: 1. Discontinued IPI-926 or withdrew informed consent to participate in original Infinity-sponsored IPI-926 study. 2. Require addition of or change to a new concomitant therapy to adequately treat the malignancy under study.
References
Publications (0)
Data not yet available
No reference posted for this study.